Related Experiment Video
Updated: Jun 20, 2026
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
New agents in chronic myelogenous leukemia
1Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas, USA. jcortes@mdanderson.org
Abstract:
Multiple new agents are currently being developed in chronic myelogenous leukemia (CML). Most of these agents are now being investigated in patients who have developed resistance to imatinib. Their mechanisms of action are diverse and many may be synergistic with imatinib. These agents will be used soon in different combinations, most likely including imatinib, with the hope of obtaining a complete blockade of the intracellular pathways that are triggered by Bcr-Abl. If this is successful, complete eradication of disease may become a reality for the majority of patients with CML.
Insights
New chronic myelogenous leukemia (CML) treatments are emerging, targeting imatinib resistance. Combinations aim for complete Bcr-Abl pathway blockade, potentially eradicating CML for most patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Chronic myelogenous leukemia (CML) treatment has advanced significantly with targeted therapies.
- Imatinib resistance is a growing challenge in managing CML.
- Understanding Bcr-Abl signaling is crucial for developing new therapeutic strategies.
Purpose of the Study:
- To review novel agents under development for chronic myelogenous leukemia.
- To explore the potential of these agents in overcoming imatinib resistance.
- To discuss the future role of combination therapies in CML management.
Main Methods:
- Review of current clinical trials and preclinical research on new CML agents.
- Analysis of the mechanisms of action for emerging targeted therapies.
- Evaluation of potential synergistic interactions between new agents and imatinib.
Main Results:
- Several new agents are in development for CML, particularly for imatinib-resistant cases.
- These agents exhibit diverse mechanisms of action, with many showing potential synergy with imatinib.
- Combination therapies, likely including imatinib, are anticipated to be a key future strategy.
Conclusions:
- New therapeutic agents offer promise for CML patients resistant to imatinib.
- Targeting Bcr-Abl pathways with novel combinations may lead to complete disease eradication.
- The future of CML treatment likely involves sophisticated combination regimens for improved patient outcomes.
